Examining High-Potency API Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Examining High-Potency API Manufacturing
High-potency manufacturing of active pharmaceutical ingredients is a growing and specialized capability.


Pharmaceutical Technology
Volume 33, Issue 7, pp. 42-46


Patricia Van Arnum
High-potency active pharmaceutical ingredients (HPAPIs) are a niche but growing area for pharmaceutical manufacturers and contract manufacturing organizations (CMOs). Specialized considerations in facility design, equipment, operation, and process safety are needed to achieve the desired level of containment of the drug substance or finished-drug product. For drug-substance manufacturing, the HPAPI may be a small-molecule, biologic, or a hybrid of the two such as an antibody–drug conjugate, which links a cytotoxic small-molecule to a monoclonal antibody.

Assessing HPAPIs

The definition of an HPAPI varies depending on the literature, but generally is defined as (1):

  • A pharmacologically active ingredient or intermediate with biological activity at approximately 150 g/kg of body weight or below in humans (therapeutic daily dose at or below 10 mg)
  • An API or intermediate with an occupational exposure limit (OEL) at or below 10 g/m3 of air as an 8-h time-weighted average
  • A pharmacologically active ingredient or intermediate with high selectivity (i.e., ability to bind to specific receptors or inhibit specific enzymes) and/or with the potential to cause cancer, mutations, developmental effects, or reproductive toxicity at low doses
  • A novel compound of unknown potency and toxicity.


IMAGES COURTESY OF SAFC
The potency of HPAPIs is characterized by OELs in g/m3. The lower the value, the more potent the compound, and the greater the level of containment required (1). OELs and related criteria such as toxicity and carcinogenicity are used in determining the performance-based exposure control limits, which link compound toxicity and potency to procedures for safe-handling of HPAPIs (1). The industry generally uses two rating programs that categorize compounds based on performance-based exposure limits, a five-tiered system or a four-tiered system, which is similar to the one developed by SafeBridge Consultants (Mountain, View, CA) (1).

Facility design, equipment, engineering controls, and the proper operation of facilities and equipment are needed to achieve the desired level of containment in HPAPI manufacturing. Operator safety is also critical and involves the use of personal protection equipment, related training in handling HPAPIs, and implementation of safe-handling practices and current good manufacturing practices (CGMPs) to prevent operator exposure and contamination (1).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here